The well-documented effects of ionising-radiation exposure include cancer[@b1][@b2], and at higher doses, various types of tissue-reaction effect, in particular circulatory disease[@b3]. Circulatory diseases have been shown to be associated with radiation treatment of malignant[@b4][@b5][@b6][@b7][@b8][@b9][@b10][@b11][@b12] and benign disease[@b13]. There is a substantial body of radiobiological data which suggests that certain inflammatory cytokines and adhesion markers thought to be involved in circulatory disease may be differentially up and down regulated at doses above and below \~0.5 Gy[@b14], suggesting that attention should be restricted to the moderate dose range \<0.5 Gy. However, risks associated with lower-dose (\<0.5 Gy) exposures remain unclear. A recent report suggested that low dose-rate space radiation exposure may increase risk of circulatory disease[@b15], although this finding is controverisal[@b16]. A meta-analysis of groups with mean exposure \<0.5 Gy indicates excess circulatory-disease risk overall for two out of four disease endpoints, but suggests that inter-cohort heterogeneity for certain endpoints limits the causal interpretability of these findings[@b17].

Previous analyses of long-term health effects with respect to circulatory disease mortality after exposure from x-ray fluoroscopy used in the course of treatment for tuberculosis have included cohorts from Canada[@b18] and Massachusetts[@b19]. There is excess mortality risk for ischaemic heart disease (IHD) in the Canadian cohort after adjusting for dose fractionation[@b18]. There is decreasing excess mortality risk with increasing age at exposure and time since exposure, but an unexpected inverse dose fractionation effect[@b18]. Although there is little evidence of excess risk overall in the Massachusetts study, at doses \<0.5 Gy there is evidence of excess mortality risk for all circulatory disease (*p* = 0.074) and IHD (*p* = 0.068)[@b19]; there are no indications of modifying effects of age at exposure, time since exposure or dose fractionation[@b19].

The purpose of this paper is to investigate circulatory disease risk in the Canadian and Massachusetts tuberculosis fluoroscopy cohorts by using a pooled data set, with a focus on the effects of radiation at doses \<0.5 Gy, and exploring also adjustments for age at exposure, time since exposure and radiation dose rate. Combining data will boost statistical power for certain rare outcomes such as hypertensive heart disease. Interpretation of the slightly different findings in the two cohorts will benefit from a unified methodological treatment.

Results
=======

In the pooled group exposed to \<0.5 Gy, there are 58,676 persons, 48,068 from the Canadian cohort and 10,608 from the Massachusetts dataset ([Table 1](#t1){ref-type="table"}) and the mean cumulative lung dose is 0.18 Gy (range = 0.01, 0.50) ([Supplementary Table S1](#S1){ref-type="supplementary-material"}). 17.4% (10,209/58,676) of patients died from circulatory disease ([Table 2](#t2){ref-type="table"}).

Under 0.5 Gy circulatory-disease mortality increases with dose (excess relative risk/Gy = 0.246; 95% CI 0.036, 0.469; *p* = 0.021) as also does IHD (excess relative risk/Gy = 0.267; 95% CI 0.003, 0.552; *p* = 0.048) ([Table 3](#t3){ref-type="table"}, [Fig. 1](#f1){ref-type="fig"}). The Kaplan-Meier plots of [Supplementary Fig. S1](#S1){ref-type="supplementary-material"} demonstrate that the survival probabilities are very similar in the various dose groups until the age of 60 years, after which point they increasingly diverge. For no disease endpoint is there any significant modifying effect of age at first exposure, or radiation dose rate (*p* \> 0.2). However, there is a pronounced (*p* \< 0.005) reduction of relative risk for all circulatory disease and IHD with increasing time since last exposure ([Table 4](#t4){ref-type="table"}, [Fig. 2](#f2){ref-type="fig"}); there are similar findings over the full dose range ([Supplementary Table S3](#S1){ref-type="supplementary-material"}). There is no modifying effect of cohort on excess relative risk for any endpoint (*p* \> 0.1) (results not shown).

Sensitivity analysis using 10-year (rather than 5-year) lag shows that there are positive dose trends for all circulatory disease (*p* = 0.018) and hypertensive heart disease (*p* = 0.027), as also to a lesser extent for IHD (*p* = 0.077) ([Supplementary Table S4](#S1){ref-type="supplementary-material"}). Over the full dose range, the sensitivity analysis in [Supplementary Table S4](#S1){ref-type="supplementary-material"} and [Supplementary Fig. S2](#S1){ref-type="supplementary-material"} demonstrate that there is a decreasing trend in mortality risk with dose for all circulatory disease (*p* = 0.014) and IHD (*p* = 0.003). Removing the upper age limit (of 100 years) makes no difference to any results (results not shown). There is limited information on antibiotic use (Isoniazid, Streptomycin, Poly-aminosalicylic acid), and diabetes, all available only for a small part (1394/13,568) of the Massachusetts dataset ([Table 1](#t1){ref-type="table"}, [Supplementary Table S2](#S1){ref-type="supplementary-material"}); information on alcohol consumption is available for the full Massachusetts cohort. These variables do not confound or otherwise modify the radiation dose response, but rather act as independent risk factors. When these variables are included in the model they have (as a group) highly significant independent effect, apart from radiation exposure, on all circulatory disease, IHD and heart disease apart from IHD and hypertensive disease (*p* \< 0.01, results not shown); the adjusted trends with dose are very similar to those of the main analysis ([Table 3](#t3){ref-type="table"}, [Supplementary Table S4](#S1){ref-type="supplementary-material"}). The significance of the ensemble of indicators is largely driven by the effects of alcohol consumption, diabetes and the indicator of the informative (for antibiotics and diabetes) subcohort of the Massachusetts dataset, which at least for all circulatory disease and IHD are conventionally statistically significant (*p* \< 0.05) ([Supplementary Table S4](#S1){ref-type="supplementary-material"}).

To assess the possibility of competing risks from causes of death other than circulatory disease, analyses of all circulatory-disease mortality using the subdistribution hazard (see Statistical Methods) yielded a risk estimate for dose \<0.5 Gy that is consistent with the main analysis (excess relative risk/Gy = 0.339; *p* = 0.002 *vs* main analysis excess relative risk/Gy = 0.246; *p* = 0.021) ([Supplementary Table S5](#S1){ref-type="supplementary-material"}). However, there is more discrepancy in the subdistribution hazard estimate for the full dose range (excess relative risk/Gy = −0.001; *p* = 0.933 *vs* main analysis excess relative risk/Gy = −0.024; *p* = 0.014) ([Supplementary Table S5](#S1){ref-type="supplementary-material"}).

Discussion
==========

We found increased radiation dose-related excess mortality risk for all circulatory disease, IHD, and hypertensive heart disease in a pooled analysis of 58,676 tuberculosis patients from Canada and Massachusetts exposed to repeated x-ray fluoroscopies and with cumulative dose \<0.5 Gy. This contrasts with analysis over the full dose range, when a negative trend in excess mortality risk with dose was observed for all circulatory disease, IHD, all deaths, and all deaths excluding circulatory disease. There is a strong reduction in radiation risk with increasing time since last exposure, but age at first exposure and radiation dose rate do not modify risk. Our findings \<0.5 Gy are robust to a variant formulation using the subdistribution hazard, suggesting that competing risks from other causes of death are operating independently from circulatory disease. However, this is not the case over the full dose range.

Our results are similar to, but somewhat stronger than those of the previous analysis of the Massachusetts cohort[@b19], which found no dose trends for any circulatory disease endpoint over the full dose range, and indications of increasing trends with dose for all circulatory disease and IHD \<0.5 Gy ([Supplementary Table S6](#S1){ref-type="supplementary-material"}). The previous analysis of the Canadian cohort[@b18] reported weaker indications of excess IHD mortality risk \<0.5 Gy ([Supplementary Table S6](#S1){ref-type="supplementary-material"}). The Canadian study also reported an increasing trend for IHD mortality with dose in the entire dose range with an inverse risk modification by dose fractionation using 10-year lag, the evidence for which became much weaker when dose was restricted to less than 0.5 Gy, or when 5-year lag was used[@b18]. We did not have individual annual doses for the Massachusetts cohort, but analyses using average dose-rates for both cohorts did not find any modification by dose-rate for dose \<0.5 Gy, or over the full dose range ([Table 4](#t4){ref-type="table"}); it may be that this somewhat different definition of radiation dose rate may account for the discrepancies in the dose-fractionation-modification findings from the previous analysis of the Canadian data[@b18].

Our findings in relation to time-since-exposure modifications to relative risk ([Table 4](#t4){ref-type="table"}, [Fig. 2](#f2){ref-type="fig"}, [Supplementary Table S3](#S1){ref-type="supplementary-material"}) are similar to those in the Canadian TB cohort[@b18] and in the Massachusetts data[@b19] over the full dose range. The absence of any strong modification of risk by age at exposure ([Table 4](#t4){ref-type="table"}, [Supplementary Table S3](#S1){ref-type="supplementary-material"}) contrasts with the pronounced inverse modification, with excess relative risk decreasing with increasing age at exposure in the Canadian TB cohort[@b18] and the modification in the opposite direction, in the Massachusetts data over the full dose range[@b19], the combination of which doubtless explains our null finding overall. In the Japanese atomic bomb survivor Life Span Study (LSS) cohort modifications to excess relative risk/Gy for age at exposure are consistent with those observed here for all endpoints[@b17]; the magnitude of the time since exposure adjustment in the LSS is inconsistent with the modification observed here for IHD ([Table 4](#t4){ref-type="table"}, [Fig. 2](#f2){ref-type="fig"}), although consistent with the adjustment for other endpoints. The modification to excess relative risk/Gy with time after exposure for IHD and cerebrovascular disease (CeVD) in a US cohort of persons who received X-radiation treatment for peptic ulcer[@b13] are consistent with those observed here. It may be significant that the type of radiation used in this study, moderate energy X-rays, is quite similar to the type of low energy, and largely unfiltered, fluoroscopy X-rays used here[@b20], albeit for therapeutic rather than diagnostic purposes, and contrasts with the rather higher energy radiation to which nuclear workers and the LSS[@b21][@b22] were exposed ([Supplementary Table S6](#S1){ref-type="supplementary-material"}); it is well known that higher-energy gamma rays are less biologically effective per unit dose than X-rays in relation to a number of experimental endpoints, in particular chromosome translocations, dicentrics, cell transformation, cell killing, specific locus mutations and various others[@b23]. Also, a typical chest fluoroscopy in the period 1930--1950, when most of the dose in the cohort was incurred, would last about 15 s and patients would receive 0.01--0.10 Gy, and thus should not be considered a low dose-rate exposure[@b24]; in this respect it is similar to the peptic ulcer study[@b13] and to the LSS[@b21][@b22], and contrasts with the generally low dose-rate exposure in most of the other moderate/low dose cohorts listed in [Supplementary Table S6](#S1){ref-type="supplementary-material"}.

A previous meta-analysis of groups exposed at low to moderate doses (mean whole-body dose \<0.5 Sv) observed excess risk for IHD and stroke, and somewhat weaker evidence of excess risk for all circulatory disease excluding heart disease and stroke[@b17]. In particular, there is excess mortality and morbidity risk in the LSS[@b21][@b22] and in various groups of nuclear workers[@b25][@b26][@b27], which are consistent with our risk estimates for all circulatory disease and IHD \<0.5 Gy ([Supplementary Table S6](#S1){ref-type="supplementary-material"}). The findings over the full dose range are somewhat inconsistent, but as above, there are indications of interference from other causes of death over this full dose range in our data. Recent reviews have proposed biological mechanisms for the effects of radiation on circulatory disease[@b14][@b28][@b29]. At high therapeutic doses \>5 Gy, damage to endothelial cells and capillaries may explain the adverse effects on the circulatory system[@b29]. At lower doses, 0.5--5 Gy, pro-inflammatory effects have been observed experimentally *in vivo* and *in vitro*, contrasting with anti-inflammatory effects at doses \<0.5 Gy[@b14][@b28][@b30]. These different biological processes corresponding to different dose ranges suggest that at low and moderate doses, in particular \<0.5 Gy, should be analysed separately from moderate and high doses. On the other hand, risk estimates in studies of medically exposed groups, which typically have organ doses much greater than 0.5 Gy[@b4][@b11][@b12][@b13][@b31], are comparable to groups exposed at lower doses ([Supplementary Table S6](#S1){ref-type="supplementary-material"}), suggesting that biological mechanism operating at high doses and dose rates may be similar to low and moderate doses and dose rates.

The present pooled analysis is the first such pooled analysis for any disease endpoints from the Canadian and Massachusetts tuberculosis fluoroscopy groups. Major strengths of the analysis are that it includes a large cohort that contains both sexes and various ages at exposure, and that has been followed through most of the 20^th^ century. Lung dose is evaluated, which should be a reasonable surrogate of dose to the heart[@b19]. The outcome and exposure information are both register-based, so most biases (e.g., due to misclassification of exposure or outcome) are unlikely. Although the combined dataset has information on smoking status and tuberculosis disease severity, both of which can modify circulatory disease risk, it lacks information on many other lifestyle factors, socio-economic status, medical risk factors for circulatory disease such as diabetes, obesity, and hypertension, also treatment-related factors for circulatory disease. Pooling data has resulted in the exclusion of variables such as alcohol consumption that is available in only one cohort[@b19]. There is limited information on alcohol consumption, antibiotic use (Isoniazid, Streptomycin, Poly-aminosalicylic acid), and diabetes, in general available only for a small part (*n* = 1394) of the Massachusetts dataset ([Table 1](#t1){ref-type="table"}, [Supplementary Table S2](#S1){ref-type="supplementary-material"}), and all derived by questionnaire to the study subjects. Analysis adjusting for these variables suggested that for certain endpoints they are highly statistically significant; nevertheless the trends with dose were very similar to those of the main analysis ([Table 3](#t3){ref-type="table"}, [Supplementary Table S4](#S1){ref-type="supplementary-material"}), implying that they do not confound the dose response. Although there is information on Isoniazid in the Canadian dataset[@b32] the data is unfortunately unavailable for the present analysis. The significance of the effect of alcohol consumption is unsurprising in view of the similar findings in the previous analysis of the Massachusetts data[@b19]. The excess risk associated with diabetes is also unsurprising, as this has been consistently identified as a risk factor for circulatory disease[@b33][@b34]. However, in radiation-exposed groups that have such lifestyle or medical information, there is no evidence that lifestyle factors interact with radiation risk of circulatory disease[@b4][@b21][@b22][@b26][@b27]. It is not expected that, conditional on calendar period, treatment for circulatory disease would be associated with fluoroscopy dose, so that it is improbable that such factors would confound the dose response.

The previous meta-analysis suggested that if the association between low-level exposure to radiation and the risk of circulatory disease reflects an underlying causal relationship, linear in dose, then the overall excess risk of mortality after exposure to low doses or low dose-rates of radiation may therefore be about twice that currently assumed[@b17]. Since the excess relative risks that are derived here are consistent with those estimated previously, the implications for low dose radiation risk are unaltered.

In conclusion, our analysis of the combined Canadian and Massachusetts tuberculosis fluoroscopy cohorts corroborate certain key findings of previous analyses of the separate cohorts. For doses under 0.5 Gy, there are increasing trends with dose for IHD, hypertensive heart disease, and all circulatory disease. Although there is no positive dose trend for circulatory disease mortality risk in the full dose range, there are indications of interference from other causes of death over this range. Fluoroscopy is still a widely used method of diagnostic imaging[@b35], in particular for interventional procedures, where doses can be considerable[@b36], so these findings have considerable significance for the long term risks that may be associated with currently used methods of radiological diagnosis.

Materials and Methods
=====================

Cohort characteristics and follow-up
------------------------------------

Medical records of patients treated for tuberculosis in all 46 Canadian institutions from 1930 to 1952 and in 12 Massachusetts hospitals from 1915 to 1968 were combined for this analysis. In the Canadian cohort multiple admissions to different institutions were identified by computerised record linkage of the patient records[@b37], resulting in a cohort of 92,707 patients. Deaths in the cohort were ascertained via computerised record linkage with the Canadian Mortality Database. Because information on cause of death is available only since 1950, we included in the cohort only those n = 68,608 known to be alive at the beginning of 1950. Exclusions were made for those with incorrect age (n = 1653), invalid last contact status or year (n = 850), age of more than 100 years at the end of follow-up (n = 2392), and other record irregularities (n = 6), leaving a cohort of 63,707 patients for analysis in the Canadian cohort. Deaths in the Massachusetts cohort were retrospectively ascertained from the Vital Statistics Offices in the state of last known residence by linking to the mortality files of the Social Security Administration and the National Death Index and by contacting relatives and friends[@b38]. Vital status was also confirmed through records from the post office, motor vehicle departments, credit bureaus, and other sources[@b39]. Of the 13,716 members of the full Massachusetts cohort, exclusions were made for lack of adequate follow-up information (n = 144), and missing last exposure date (n = 4), leaving an analysis dataset of 13,568 persons. The combined cohort therefore contains 77,275 patients, 63,707 (82%) from the Canadian data and 13,568 (18%) from the Massachusetts study. More details about the methods used to assemble the separate cohorts can be found in earlier publications[@b39][@b40][@b41]. Details of individual dates of entry and exit from treatment, smoking status (unknown smoking status/ever smoker/never smoker), and most advanced stage of TB recorded (unknown/minimal/moderate/advanced) were abstracted from medical treatment records, and for some lifestyle data available for both cohorts (e.g., smoking) via interviews and questionnaires. For a group of 1502 members of the Massachusetts cohort (1472 with lung dose \<0.5 Gy) with more than a single fluoroscopy the start and end of exposure dates are only known to be within a given calendar year; for these individuals the initial and final exposures were assumed to be separated by 4 months (\~third of a year), the theoretically-expected separation for dates constrained to lie within a year. 404/13,568 cohort members with vital status not known after a certain date had follow-up censored then.

The study entry date is defined as the later of the entry date into the sanatoria for treatment beginning in 1915, and in the Canadian cohort, January 1, 1950. Follow-up ended on the earlier of the loss to follow-up, date of death, or December 31, 1987 for the Canadian cohort, or December 31, 2002 for the Massachusetts cohort.

The causes of death were recoded to the International Classification of Diseases, Ninth Revision (ICD-9)[@b42]. Our study focuses on deaths from all circulatory diseases and individual analysis of IHD, CeVD, hypertensive heart disease, heart disease apart from IHD and hypertensive heart disease, and other circulatory diseases, with associated ICD-9 codes given in [Table 2](#t2){ref-type="table"}. All information is for underlying cause of death. There is no information available to the investigators on contributing causes of death in either cohort.

Dosimetry
---------

Dosimetry methods for each cohort are detailed elsewhere[@b18][@b19][@b43]. In both cohorts, dose estimation accounted for the number of fluoroscopic screenings, data of typical fluoroscopic procedures during the period of exposure, and phantom studies[@b43]. Radiation doses to the lungs during fluoroscopic screenings were treated as surrogate doses to the heart and circulatory system. The fluoroscopy fields would encompass the heart more completely (i.e., the heart generally would be in the direct beam and also receive additional scattered radiation from the rest of the field); the fluoroscopy fields would not always encompass both lungs, so sometimes the lungs would be partially irradiated. Lung dose would therefore generally be expected to be slightly lower than heart dose, possibly by as much as a factor of 2[@b19][@b44].

Statistical methods
-------------------

Person-years at risk were calculated for each stratum defined by cohort (Canada or Massachusetts), sub-cohort (Nova Scotia/non-Nova Scotia Canadian, Massachusetts I/II/III[@b39]), gender, tuberculosis stage, smoking status, attained age, calendar year at risk, cumulative lagged dose and dose rate categories; missing data were separately coded and incorporated into the person-year table. Sensitivity analyses were also conducted in which the upper age limit (of 100 years) was removed. In contrast to previous analyses of the Canadian data which used individual annual doses and actual duration of fluoroscopic procedures[@b18], the current analyses assumed that dose was uniformly distributed over the exposure duration (=date discharge − date entry to sanatorium), so as to be comparable with the previous analysis of the Massachusetts cohort[@b19] for which annual doses are not available. Dose rate was defined as the ratio: cumulative dose/exposure duration. For most analyses, the dose lag (and time from start of follow-up to entry into the analysis dataset) was 5 years, but a 10 year dose lag (and entry lag) was also assessed.

We modelled the relative risk (RR) for circulatory disease mortality using Poisson regression[@b45], so that the expected number of deaths in stratum *i* (defined by the above non-dose variables) and dose group *j* with mean dose *D*~*ij*~ and mean person year *PY*~*ij*~ of follow-up is:

for some auxiliary modifying variables , which included age at first exposure, time since last exposure and doserate. The model is linear in radiation dose, analogous to models previously used to assess circulatory disease in radiation exposed populations[@b13][@b17][@b22]. The excess relative risk per Gy *α*, the baseline mortality-rate modifying parameters *γ*~*k*~, the excess relative risk modifying parameters , and the semi-parametric background rate *λ*~*i*~ were estimated from the model fit. In analysis adjusting for antibiotic use (Isoniazid, Streptomycin, Poly-aminosalicylic acid), and diabetes, we employ an indicator of the informative part of the Massachusetts cohort, and indicators for the presence of each of these exposures or medical conditions, adjusting the background risk via the parameters *γ*~*k*~; the results of the analysis adjusting for these variables and alcohol consumption (again adjusting the background risk via the parameters *γ*~*k*~) are provided in [Supplementary Table S4](#S1){ref-type="supplementary-material"}. Sensitivity to the effects of competing risks from other types of mortality was assessed by fitting a Poisson model analogous to the subdistribution hazard of Fine and Gray[@b46], which assumes that patients that died from causes other than circulatory disease were censored at the last day of follow-up in each cohort. Parameter estimation was by likelihood maximisation[@b45] and was conducted in EPICURE[@b47]. All hypothesis tests were 2-sided. When possible, confidence intervals were estimated from the profile likelihood[@b45], otherwise by Wald test inversion. [Supplementary Table S6](#S1){ref-type="supplementary-material"} cites results from a number of studies, some not already referenced in the main text[@b48][@b49][@b50][@b51][@b52][@b53][@b54][@b55][@b56][@b57][@b58][@b59][@b60][@b61][@b62].
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![Relative risk estimates (and their 95% confidence intervals) against cumulative lagged dose (lagged by 5 years) for the restricted dose range \[0, 0.5\] Gy.\
We show results for the dose categories 0--0.049, 0.050--0.099, 0.100--0.149, 0.150--0.199, 0.200--0.299, 0.300--0.499 Gy. The dashed red line corresponds to relative risk =1.](srep44147-f1){#f1}

![Variation of excess relative risk (+95% CI) with years since last exposure for all circulatory disease and ischaemic heart disease.\
We show results for the categories 0--19, 20--29 and ≥30 years since last exposure.](srep44147-f2){#f2}

###### Counts of patients for the Canadian and Massachusetts by demographic and exposure variables.

   Descriptive characteristics     Categories      Numbers with lung dose \<0.5 Gy/dose unrestricted                          
  ----------------------------- ----------------- --------------------------------------------------- ----------------------- -----------------------
        Canadian province          Nova Scotia                         3431/4408                                0/0                  3431/4408
         non-Nova Scotia          44,637/59,299                           0/0                              44,637/59,299      
     Massachusetts subcohort     Massachusetts I                          0/0                                1101/1744               1101/1744
        Massachusetts II               0/0                             5327/6986                             5327/6986        
        Massachusetts III              0/0                             4180/4838                             4180/4838        
             Gender                  female                          23,295/31,787                           4934/6633             28,229/38,420
              male                24,773/31,920                        5674/6935                           30,447/38,855      
         Smoking status               never                            2447/3456                             2530/3390               4977/6846
              ever                 7099/10,172                         5108/6474                           12,207/16,646      
             unknown              38,522/50,079                        2970/3704                           41,492/53,783      
         Alcohol status               never                               0/0                                5392/7013               5392/7013
              ever                     0/0                             2633/3281                             2633/3281        
             unknown                   0/0                             2583/3274                             2583/3274        
       Tuberculosis status           minimal                         12,899/15,264                           2187/2643             15,086/17,907
            moderate              15,299/22,696                        3848/5229                           19,147/27,925      
            advanced              10,609/16,253                        3832/4932                           14,441/21,185      
           unrecorded               9261/9494                           741/764                            10,002/10,258      
       Age at entry, year             0--19                          10,447/14,249                           1344/1804             11,791/16,053
             20--39               26,806/37,655                        5220/7399                           32,026/45,054      
             40--59                 8803/9765                          3019/3322                           11,822/13,087      
               ≥60                  2012/2038                          1025/1043                             3037/3081        
   Age at first exposure, year    not screened                       38,775/38,775                           7229/7229             46,004/46,004
              0--19                 1295/4500                          412/1098                              1707/5598        
             20--39                6570/17,888                         2207/4210                            8777/22,098       
             40--59                 1363/2448                           712/971                              2075/3419        
               ≥60                    65/96                              49/60                                113/156         
    Age at study exit, years          0--54                           9222/11,696                            2834/3562             12,056/15,258
             55--64               14,025/19,117                        1635/2014                           15,660/21,131      
             65--74               14,470/20,818                        2635/3286                           17,105/24,104      
               ≥75                10,351/12,676                        3504/4706                           13,855/17,382      
    Cumulative lung dose, Gy            0                            38,775/38,775                           7754/7754             46,529/46,529
            \>0--0.49               9293/9293                          2854/2854                           12,147/12,147      
           0.50--0.99                0/5038                             0/1123                                0/6161          
           1.00--1.99                0/6343                             0/1241                                0/7584          
              ≥2.00                  0/4258                              0/596                                0/4854          
     Lung dose rate, Gy/year            0                            38,775/38,775                           7754/7754             46,529/46,529
           \>0.0--0.19              2308/3141                          1271/1562                             3579/4703        
           0.20--0.49               2585/9429                          1040/2777                            3625/12,206       
           0.50--4.99              4387/12,349                         543/1475                             4930/13,824       
              ≥5.00                   13/13                               0/0                                  13/13          
            **Total**                                            **48,068**/**63,707**                 **10,608**/**13,568**   **58,676**/**77,275**

In each cell we provide numbers of persons with cumulative dose \<0.5 Gy (to the left of the oblique dash) and without restriction on dose (to the right of the oblique dash) in the respective cohorts (Canada, Massachusetts, total (Canada + Massachusetts)).

###### Mortality counts by disease endpoint in the Canadian and Massachusetts cohorts, in relation to dose range, attained age range, lag period from start of follow-up to entry into analysis cohort.

                 Endpoint/type of circulatory disease                          ICD9 codes            Number of deaths/person years            
  ------------------------------------------------------------------ ------------------------------ ------------------------------- --------- -----------
             Lung dose \< 0.5 Gy, age \< 100, lag 5 years                                                                                     
                       Cerebrovascular disease                                  430--438                         1192                  369       1561
                       Ischaemic heart disease                                  410--414                         4876                 1534       6410
                      Hypertensive heart disease                                401--405                          181                  63         244
             Heart disease apart from IHD + hypertensive              390--400, 406--409, 415--429                926                  383       1309
   All other circulatory disease apart from heart + cerebrovascular             439--459                          518                  167        685
                       All circulatory disease                                  390--459                         7693                 2516      10,209
                        Person years follow-up                                                                 1,179,270             247,711   1,426,981
           Lung dose unrestricted, age \< 100, lag 5 years                                                                                    
                       Cerebrovascular disease                                  430--438                         1481                  472       1953
                       Ischaemic heart disease                                  410--414                         6211                 1947       8158
                      Hypertensive heart disease                                401--405                          234                  89         323
             Heart disease apart from IHD + hypertensive              390--400, 406--409, 415--429               1182                  497       1679
   All other circulatory disease apart from heart + cerebrovascular             439--459                          659                  211        870
                       All circulatory disease                                  390--459                         9767                 3216      12,983
                        Person years follow-up                                                                 1,599,120             345,921   1,945,041
        Lung dose unrestricted, age unrestricted, lag 0 years                                                                                 
                       Cerebrovascular disease                                  430--438                         1585                  493       2078
                       Ischaemic heart disease                                  410--414                         6516                 2086       8602
                      Hypertensive heart disease                                401--405                          286                  102        388
             Heart disease apart from IHD + hypertensive              390--400, 406--409, 415--429               1330                  543       1873
   All other circulatory disease apart from heart + cerebrovascular             439--459                          701                  222        923
                       All circulatory disease                                  390--459                        10,418                3446      13,864
                        Person years follow-up                                                                 1,904,580             405,193   2,309,773

###### Excess relative risk estimates for circulatory disease mortality endpoints by dose range using 5 year dose lag and 5 years from study entry to start of follow-up.

              Dose range, Gy              Excess relative risk/Gy (+95% confidence intervals (CI))                                                                                                     
  -------------------------------------- ---------------------------------------------------------- ----------------------- ----------------------- ------------------------ ------------------------- ------------------------
                 0--0.10                                   1.135 (−0.494, 2.900)                     1.371 (−0.708, 3.664)   1.998 (−2.102, 7.027)   15.340 (2.298, 35.100)   −1.586 (−4.990, 2.759)    −1.724 (−6.643, 5.339)
   *p*-value[a](#t3-fn1){ref-type="fn"}                            0.177                                     0.204                   0.367                   0.015                     0.443                    0.589
                 0--0.20                                   0.322 (−0.444, 1.151)                     0.618 (−0.353, 1.687)   0.979 (−1.043, 3.453)   −0.448 (−4.791, 7.003)   −1.121 (−2.726, 0.914)    −0.564 (−3.212, 3.143)
   *p*-value[a](#t3-fn1){ref-type="fn"}                            0.421                                     0.221                   0.370                   0.882                     0.257                    0.733
                 0--0.30                                   0.371 (−0.006, 0.772)                     0.490 (0.013, 1.006)    0.915 (−0.101, 2.109)    3.033 (0.169, 7.216)    −1.292 (−1.998, −0.417)   0.856 (−0.622, 2.749)
   *p*-value[a](#t3-fn1){ref-type="fn"}                            0.054                                     0.044                   0.080                   0.035                     0.006                    0.283
                 0--0.40                                    0.268 (0.002, 0.551)                     0.337 (0.001, 0.699)    0.661 (−0.059, 1.499)   1.065 (−0.746, 3.711)    −0.588 (−1.131, 0.064)    0.540 (−0.531, 1.892)
   *p*-value[a](#t3-fn1){ref-type="fn"}                            0.049                                     0.049                   0.074                   0.290                     0.075                    0.352
                 0--0.50                                    0.246 (0.036, 0.469)                     0.268 (0.003, 0.552)    0.441 (−0.119, 1.090)   1.121 (−0.351, 3.228)    −0.226 (−0.679, 0.307)    0.507 (−0.322, 1.541)
   *p*-value[a](#t3-fn1){ref-type="fn"}                            0.021                                     0.047                   0.129                   0.155                     0.385                    0.253

^a^*p*-value for departure of trend from null. All models adjust for cohort/sub-cohort, gender, smoking status, tuberculosis status, attained age, calendar year at risk by stratification. All CI are profile-likelihood based.

###### Excess relative risk (ERR) estimates (and 95% confidence intervals (CI)) and adjustment factors for circulatory disease mortality endpoints (and 95% CI) for 0--0.5 Gy dose range in models that adjust for (a) age at first exposure, (b) years since last exposure or (c) radiation dose rate.

                                Type of adjustment to ERR/Gy                                 Excess relative risk/Gy (+95% CI)/% adjustment (+95% CI)/*p*-value                                                                                                                                                                                                                                                                                                    
  ----------------------------------------------------------------------------------------- -------------------------------------------------------------------- -------------------------------------------------- ------------------------------------------------------------------------------ ------------------------------------------------------------------------------- ------------------------------------------------------------------------------- -------------------------------------------------------------------------------
                      Linear ERR/Gy adjusted for age at first exposure                                              0.165 (0.013, 0.478)                          0.214 (−0.088[a](#t4-fn1){ref-type="fn"}, 0.544)                 0.510 (−0.159[a](#t4-fn1){ref-type="fn"}, 1.242)                               1.166 (−0.688[a](#t4-fn1){ref-type="fn"}, 3.456)                                −0.236 (−0.664, 0.309[a](#t4-fn1){ref-type="fn"})                               0.461 (−0.621[a](#t4-fn1){ref-type="fn"}, 1.688)
   Age at first exposure adjustment (% change in ERR/Gy per year of age at first exposure)                           −13.0 (−25.8, 8.5)                                          3.2 (−32.5, 25.9)                     −4.3 (−18.3[a](#t4-fn1){ref-type="fn"}, 12.1[a](#t4-fn1){ref-type="fn"})       −0.8 (−14.2[a](#t4-fn1){ref-type="fn"}, 14.6[a](#t4-fn1){ref-type="fn"})         3.6 (−7.9[a](#t4-fn1){ref-type="fn"}, 16.7[a](#t4-fn1){ref-type="fn"})          1.2 (−13.2[a](#t4-fn1){ref-type="fn"}, 17.9[a](#t4-fn1){ref-type="fn"})
                *p*-value[b](#t4-fn2){ref-type="fn"} for modification of ERR                                               0.251                                                       0.552                                                            0.593                                                                           0.890                                                                           0.353                                                                           0.899
                     Linear ERR/Gy adjusted for time since last exposure                              0.272 (−0.024[a](#t4-fn1){ref-type="fn"}, 0.582)            0.215 (−0.109[a](#t4-fn1){ref-type="fn"}, 0.659)                 0.540 (−0.203[a](#t4-fn1){ref-type="fn"}, 1.338)                               1.047 (−0.824[a](#t4-fn1){ref-type="fn"}, 3.179)                                             −0.215 (−0.701, 0.408)                                             0.007 (−0.059[a](#t4-fn1){ref-type="fn"}, 1.387)
   Years since last exposure adjustment (% change in ERR/Gy per year since last exposure)                           −10.5 (−49.2, −3.9)                                         −14.7 (−42.6, −6.4)                    −6.1 (−17.3[a](#t4-fn1){ref-type="fn"}, 6.5[a](#t4-fn1){ref-type="fn"})         1.6 (−8.5[a](#t4-fn1){ref-type="fn"}, 13.0[a](#t4-fn1){ref-type="fn"})          0.6 (−14.2[a](#t4-fn1){ref-type="fn"}, 17.9[a](#t4-fn1){ref-type="fn"})         21.6 (−7.9[a](#t4-fn1){ref-type="fn"}, 60.6[a](#t4-fn1){ref-type="fn"})
                *p*-value[b](#t4-fn2){ref-type="fn"} for modification of ERR                                               0.002                                                      \< 0.001                                                          0.402                                                                           0.693                                                                           0.899                                                                           0.244
                            Linear ERR/Gy adjusted for dose rate                                                    0.247 (0.036, 0.470)                          0.268 (−0.014[a](#t4-fn1){ref-type="fn"}, 0.551)                              0.467 (−0.101, 1.117)                                             1.108 (−0.633[a](#t4-fn1){ref-type="fn"}, 3.220)                                −0.228 (−0.678, 0.379[a](#t4-fn1){ref-type="fn"})                               0.500 (−0.467[a](#t4-fn1){ref-type="fn"}, 1.535)
                    Dose rate adjustment (% change in ERR/Gy per Gy/year)                                           3.11 (−95.85, 67.50)                                       −19.32 (−99.28, 60.32)                32.51 (−30.36[a](#t4-fn1){ref-type="fn"}, \> 100[a](#t4-fn1){ref-type="fn"})   −20.05 (−98.62[a](#t4-fn1){ref-type="fn"}, \> 100[a](#t4-fn1){ref-type="fn"})   −59.51 (−99.98[a](#t4-fn1){ref-type="fn"}, \> 100[a](#t4-fn1){ref-type="fn"})   −22.65 (−99.63[a](#t4-fn1){ref-type="fn"}, \> 100[a](#t4-fn1){ref-type="fn"})
                *p*-value[b](#t4-fn2){ref-type="fn"} for modification of ERR                                               0.950                                                       0.684                                                            0.565                                                                           0.877                                                                           0.570                                                                           0.847

^a^Wald-based CI.

^b^2-sided *p*-value for departure of trend from null.

All models adjust for cohort/sub-cohort, gender, smoking status, tuberculosis status, attained age, calendar year at risk by stratification. All CI are profile-likelihood based. The adjustments for age at first exposure, years since last exposure and dose rate are centered at the person-year-weighted mean values for the \<0.5 Gy data, namely 27.98 years, 25.09 years and 0.61 Gy/year, respectively. 5 year dose lag and period from entry to start of follow-up. Unless otherwise stated all CI are based on the profile likelihood.
